Sun, Xiujie
Wu, Bogang http://orcid.org/0000-0003-1654-198X
Chiang, Huai-Chin http://orcid.org/0000-0002-7616-3362
Deng, Hui
Zhang, Xiaowen
Xiong, Wei
Liu, Junquan
Rozeboom, Aaron M.
Harris, Brent T.
Blommaert, Eline http://orcid.org/0000-0003-0040-5158
Gomez, Antonio http://orcid.org/0000-0001-5308-981X
Garcia, Roderic Espin http://orcid.org/0000-0003-2494-0964
Zhou, Yufan http://orcid.org/0000-0002-8385-433X
Mitra, Payal
Prevost, Madeleine
Zhang, Deyi
Banik, Debarati
Isaacs, Claudine
Berry, Deborah
Lai, Catherine
Chaldekas, Krysta
Latham, Patricia S. http://orcid.org/0000-0003-2782-9444
Brantner, Christine A.
Popratiloff, Anastas
Jin, Victor X. http://orcid.org/0000-0002-8765-3471
Zhang, Ningyan http://orcid.org/0000-0002-4348-2180
Hu, Yanfen
Pujana, Miguel Angel http://orcid.org/0000-0003-3222-4044
Curiel, Tyler J. http://orcid.org/0000-0001-6962-9411
An, Zhiqiang http://orcid.org/0000-0001-9309-2335
Li, Rong http://orcid.org/0000-0002-6471-6580
Article History
Received: 18 October 2019
Accepted: 22 September 2021
First Online: 3 November 2021
Competing interests
: X.S., H.D., N.Z., Z.A. and R.L. are co-inventors of a pending patent application (62/949,300) filed by the University of Texas Health Science Center at Houston on the anti-DDR1 antibodies described in this manuscript. The University of Texas System and The George Washington University have licensed the patent to Parthenon Therapeutics for drug development. R.L. receives stock option and financial compensation for his role as a member on the Scientific Advisory Board of Parthenon Therapeutics.